This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

CAMBRIDGE, Mass. (AP) — Moderna announced Thursday it is beefing up global manufacturing of its COVID-19 vaccine in an effort to produce up to 3 billion doses in 2022.

The company predicts supplying between 800 million and 1 billion doses worldwide this year. But it’s looking ahead as much of the world still needs a first round of COVID-19 vaccinations next year — and to be ready if and when people may need a booster shot.

Moderna’s vaccine is authorized for use by adults in the U.S., European Union and multiple other countries. The company expects data soon from a U.S. study of the two-dose vaccine in 12 to 17-year-olds, and has begun testing the shots in younger children.

Also underway are studies of doses tweaked to better match a worrisome mutated version of the coronavirus.